Redman A M, Johnson J S, Dally R, Swartz S, Wild H, Paulsen H, Caringal Y, Gunn D, Renick J, Osterhout M, Kingery-Wood J, Smith R A, Lee W, Dumas J, Wilhelm S M, Housley T J, Bhargava A, Ranges G E, Shrikhande A, Young D, Bombara M, Scott W J
Department of Chemistry Research, Bayer Research Center, Pharmaceutical Division, West Haven, CT 06516, USA.
Bioorg Med Chem Lett. 2001 Jan 8;11(1):9-12. doi: 10.1016/s0960-894x(00)00574-6.
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.
